Abstract:Combined small cell lung cancer (CSCLC), a rare subtype of SCLC, accounts for only 2% to 5% of all lung cancers, and little is known about the clinicopathologic characteristics and molecular changes in the various histologic components. Here, we first reported a patient of CSCLC with adenocarcinoma harboring the same kinesin light chain 1 (KLC1)–anaplastic lymphoma kinase (ALK) fusion in both histologic components. A 68-year-old female ex-smoker (50 pack-years) presented an abnormal shadow in the left lung, and computed tomography revealed a 5-cm irregular solitary mass during examination with no other significant medical history. Puncture biopsy revealed a malignant neoplasm with poor differentiation. Then the patient underwent a pulmonary lobectomy with systematic mediastinal lymphadenectomy through minimally invasive muscle-sparing thoracotomy. Histopathologically, the tumor consisted of dual disparate components, which were intermingled in a combined pattern with a definite boundary at low magnification (Fig. 1A). At high power, the central component was composed of small, uniform, and poorly differentiated carcinoma with necrosis (Fig. 1B), which should be diagnosed as SCLC, and was approximately 40% of the entire tumor, while the surrounding area was adenocarcinoma (60%) with papillary and acinar components (Fig. 1C). Immunohistochemically, both components were strongly positive for cytokeratin 7 and thyroid transcription factor 1 (TTF1) (Figs. 1D and E). In contrast, only the component of SCLC was positive for synaptophysin (Syn), chromogranin A (CgA) and neural cell adhesion molecule 1 (CD56), with high proliferation activity by Ki-67 antigen immunostaining, whereas the area of adenocarcinoma was negative for those markers, with low Ki-67 proliferation activity (Figs. 1F and G). The pathologic stage was finally determined as pT2N0M0 with no evidence of local invasion and systemic metastasis. Intriguingly, the tumor cells of both histologic components showed diffusely and strongly positive for ALK (D5F3 rabbit monoclonal antibody, Ventana Medical Systems, Tucson, AZ) (Figs. 1H and I). Fluorescence in situ hybridization confirmed the presence of ALK rearrangement in both components, but with different signals. The SCLC component showed only one pair of split 3’ (red) and 5’ (green) signals, whereas the component of adenocarcinoma showed one or two pairs of 3’ and 5’ fused signals (yellow) plus one isolated3’ signal (Figs. 1J and K). To determine ALK gene alterations in both components, targeted next-generation sequencing (NGS), including 68 lung cancer related genes (Supplemental Table 1), was performed in each of the components, respectively. As a result, the same ALK rearrangement, collectively known as KLC1-ALK fusion, which was created by KLC1 exon 9 and ALK exon 20 (Figs. 1L and M), was identified in both components, suggesting that ALK rearrangements could be involved in the pathogenesis of both adenocarcinoma and SCLC, as previous case reported by Toyokawa, which could be successfully treated with ALK inhibitors.1Toyokawa G. Taguchi K. Ohba T. et al.First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component.J Thorac Oncol. 2012; 7: e39-e41Abstract Full Text Full Text PDF PubMed Scopus (43) Google Scholar, 2Wang P. Xiao P. Ye Y. et al.Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non–small cell lung cancer: a case report.Cancer Biol Med. 2017; 14: 183-186Crossref PubMed Scopus (12) Google Scholar The results also provided some preliminary evidence that the two histologic components of SCLC and adenocarcinoma might be a monoclonal origin, consistent with the previous study in the lung and gastrointestinal tract.3Zhao X. McCutcheon J.N. Kallakury B. et al.Combined small cell carcinoma of the lung: is it a single entity?.J Thorac Oncol. 2018; 13: 237-245Abstract Full Text Full Text PDF PubMed Scopus (34) Google Scholar, 4Scardoni M. Vittoria E. Volante M. et al.Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract: targeted next-generation sequencing suggests a monoclonal origin of the two components.Neuroendocrinology. 2014; 100: 310-316Crossref PubMed Scopus (91) Google Scholar They might develop to different histologic types, such as squamous cell carcinoma, adenocarcinoma, and large cell neuroendocrine carcinoma, with other different driver gene mutations. In addition, analysis of targeted NGS revealed that RB transcriptional corepressor 1 (RB1) copy number deletion, a hallmark of SCLC, was only in the SCLC component, while phosphate and tensin homolog (PTEN) frameshift mutation (c.987_990del, NM_000314.6) was only in the component of adenocarcinoma, suggesting potential therapeutic targets for cyclin dependent kinase (CDK) and mechanistic target of rapamycin kinase (mTOR) inhibitors in CSCLC for their functional effects of RB1 loss and PTEN mutations.5George J. Lim J.S. Jang S.J. et al.Comprehensive genomic profiles of small cell lung cancer.Nature. 2015; 524: 47-53Crossref PubMed Scopus (1214) Google Scholar, 6Spring L. Bardia A. Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions.Discov Med. 2016; 21: 65-74PubMed Google Scholar, 7Meric-Bernstam F. Akcakanat A. Chen H. et al.PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.Clin Cancer Res. 2012; 18: 1777-1789Crossref PubMed Scopus (178) Google Scholar The authors thank Ling Shan, PhD, Mengjiao Wang, MD, PhD, Heng Chang, BS, Longlong Bao, MD, and Cong Tan, MD, for academic support. This work was supported by grants from the National natural Foundation Science of China (NSFC 81401939). Download .docx (.02 MB) Help with docx files Supplementary Table 1

Sustained Clinical Response to 4th-Line Therapy with Selpercatinib in RET Fusion-Positive Combined Small Cell Lung Cancer

Small cell lung carcinoma with KIF5B-RET fusion partially responded to the 4 th -line therapy with anlotinib: A case report

Intracranial Activity of Selpercatinib in Chinese Patients With Advanced <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial

Efficacy and Safety of Selpercatinib in Chinese Patients with Advanced RET Fusion-Positive Non-Small-cell Lung Cancer: a Phase II Clinical Trial (LIBRETTO-321).

Response to selpercatinib in a patient with RET fusion-positive pulmonary large-cell neuroendocrine carcinoma: A case report

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Selpercatinib Monotherapy in a Chinese Patient with RET Fusion/ EGFR Co-Mutated Nonsmall Cell Lung Cancer from the Phase II LIBRETTO-321 Study: a Case Report.

First-line selpercatinib for a patient with RET fusion-positive pulmonary large cell neuroendocrine carcinoma

CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].

Patient-reported outcomes following selpercatinib treatment in Chinese patients with advanced <i>RET</i> fusion-positive non-small-cell lung cancer and thyroid cancer, and <i>RET</i>-mutant medullary thyroid cancer in the phase II LIBRETTO-321 trial

A Case of Primary Pulmonary Combined Small Cell Carcinoma with Adenocarcinoma Harboring the Same KLC1-ALK Fusion in Both Histologic Components

1P19q Codeletion and RET Rearrangements in Small Cell Lung Cancer.

Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition

RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report

Combined Dacomitinib and Selpercatinib Treatment for a Patient with EGFR-Mutant Non-Small Cell Lung Cancer and Acquired CCDC6-RET Fusion

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)

Abstract 5835: Genome-Wide CRISPR gene knockout screens combined with selpercatinib identifies potent combination therapies for RET driven medullary thyroid carcinoma

Longitudinal detection of subcategorized CD44v6 + CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center study

Case Report: A case of ultra-late recurrence of KIF13A-RET fusion non-small cell lung cancer response to selpercatinib

Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer